Announcing: Symposium on hadrontherapy in Caen – A Milestone for HITRIplus

The Symposium “From Proton to Heavy Ions Radiotherapy” will take place in Caen on March 10-11, 2025, celebrating the final assembly of the C400 superconducting heavy-ion cyclotron. This event marks an exciting milestone for the HITRIplus project, uniting leading minds in radiotherapy to explore the latest innovations and clinical applications of heavy-ion technology. Additionally, the signing of a Memorandum of Understanding (MOU) with Caen underscores a shared commitment to advancing heavy-ion therapy and fostering collaborative efforts in this critical field.

Highlights of the Symposium:

• Expert Contributions from HITRIplus: The symposium program is being designed with valuable input from HITRIplus experts, who bring a wealth of knowledge to discussions on advancing particle therapy. Among the potential speakers:
  • Prof. Marco Durante – A pioneer in physics and radiobiology from GSI and PTCOG.
  • Prof. Manjit Dosanjh – A specialist in radiobiology from the University of Oxford and CERN, with a focus on integrating biological insights into radiotherapy.
  • Dr. Sandro Rossi – Director General of CNAO and a driving force in physics and management within HITRIplus.
• Cutting-edge Scientific Sessions: Topics will cover technological developments in cyclotron-based radiotherapy, treatment planning advancements, and radiobiological insights, including molecular, cellular, and clinical models for particle therapy.
• Clinical Applications: Sessions on clinical indications will address the latest findings in particle therapy applications for cancers such as pancreatic and pediatric tumors, focusing on patient selection strategies in Europe and Asia.
• Economic Perspectives: The program includes a session dedicated to the medico-economics of hadron therapy, exploring cost-benefit models and the importance of clinical networks for patient referrals and international collaborations.

This symposium is a must-attend for anyone involved in radiotherapy and oncology, offering an unparalleled opportunity to connect with HITRIplus experts and gain insights into the future of heavy-ion radiotherapy. Further details will be shared soon—stay connected with HITRIplus, CYCLHAD, and UNICAEN for updates.